|
 |
RTOG Reports Recent Cancer Trial Results in 22 Presentations at ASTRO
Philadelphia, September 16, 2008 - Radiation Therapy Oncology Groups (RTOG) investigators will report recent results from the group's research during 22 presentations at the at the American Society for Therapeutic Radiology and Oncology (ASTRO) 50th Annual Meeting in Boston, MA, September 21 - 25, 2008. RTOG, a National Cancer Institute funded national clinical trials group, is a clinical research component of the American College of Radiology.
"For the last 40 years RTOG has conducted high quality clinical cancer research involving radiation therapy," said Walter J. Curran, Jr., the RTOG Group Chair, and the Lawrence W. Davis Professor and Chair of the Department of Radiation Oncology in the Emory School of Medicine and Chief Medical Officer of the Emory Winship Cancer Institute. "The research that RTOG members are presenting at ASTRO demonstrates the breath of the group's clinical investigations. Several of these abstracts report on our testing of advanced technologies in the multi-modality settings coupled with translational and quality-of-life research questions."
The 22 oral and poster presentations highlight some of the group's recent research in breast, central nervous system, gynecologic, head & neck, lung, pancreatic, and prostate malignancies. Attached is a complete list the RTOG presentations at ASTRO.
# # #
Please visit the RTOG booth (2247) in the Boston Convention and Exhibition Center. If you would like a copy of an RTOG abstract contact or to arrange to speak with an RTOG author please visit the RTOG booth or contact Sharon Hartson Stine 609-458-4504, shartson@acr-arrs.org).
RTOG Presentations at ASTRO 2008
| Bone Metastases | |
| Functional Interference Clusters in Cancer Patients with Bone Metastases: An Analysis of RTOG 9714.
Chow, E., James, J., Barsevick, A., Hartsell, W., Scarantino, C., Ivker, R., Roach III, M., Suh, J., Petersen, I. and Bruner, D. |
Poster Discussion: 1062
Tues., 9/23, 1:45 PM
Session 5, Room 156
|
| Brain Tumors | |
| An Update on Correlative Molecular Endpoints from RTOG 0211: Phase I/II Study of Gefitinib + Radiation for Newly Diagnosed Glioblastoma Patients.
Chakravarti, A., Wang, M., Mischel, P., Robins, I., Guha, A., Machtay, M., Curran, W., Roach, M., Mehta, M. and Dicker, A. |
Oral Presentation: 20
Mon., 9/22, 10:25 AM
Session C, Room 254
|
A Randomized Trial of Chemotherapy plus Radiotherapy (RT) versus RT alone for Anaplastic Oligodendroglioma (RTOG 9402): The Perspective of Longer Follow-Up.
Cairncross, G., Wang, M., Chang, S., Shaw, E., Jenkins, R., Scheithauer, B., Buckner, J., Fink, K., Mehta, M. and Curran, W. |
Platform: 16
Mon., 9/22, 10:45 AM
Session B, Room 107 |
| Patterns of Missing Mini Mental Status Exam Data in Radiation Therapy Oncology Group (RTOG) Brain Tumor Trials.
Bae, K., Bruner, D., Yan, Y., Coyne, J. and Movsas, B. |
Poster: 2736
Poster - Exhibition Hall |
| The Prognostic Value of Nestin Expression in Newly Diagnosed GBM: Report from the RTOG.
Chinnaiyan, P., Wang, M., Rojiani, A., Tofilon, P., Chakravarti, A., Ang, K., Zhang, H.-Z., Hammond, E., Curran, J., W and Mehta, M. |
Poster: 2083
Poster - Exhibition Hall |
| Breast Cancer | |
| Initial Efficacy Results of RTOG 0319: Three Dimensional Conformal Radiation Therapy (3D-CRT) Confined to the Region of the Lumpectomy Cavity for Stage I/ II Breast Carcinoma.
Vicini, F., Winter, K., Wong, J., Pass, H., Rabinovitch, R., Chafe, S., Arthur, D., Petersen, I., White, J. and McCormick, B.
| Oral Presentation: 6
Mon., 9/22, 10:25 AM
Session A, Room 253 |
| Gynecologic Cancer | |
| Changes in Gene Expression Predicting Local Control in Cervical Cancer: Results from RTOG 0128.
Weidhaas, J., Li, S., Winter, K., Ryu, J., Jhingran, A., Miller, B., Dicker, A. and Gaffney, D. |
Oral Presentation: 34
Mon., 9/22, 10:15 AM
Session E, Room 257 |
| ERCC1, COX-2, and p53 Expression in Patients with Locally Advanced Cervical Cancer Treated with Chemoradiotherapy and Celecoxib: A Quantitative Immunohistochemical Analysis of RTOG 0128.
Doll, C., Winter, K., Gaffney, D., Ryu, J., Jhingran, A., Dicker, A., Weidhaas, J., Miller, B. and Magliocco, A. |
Poster: 2415
Poster - Exhibition Hall |
| A Phase II Study of Intensity Modulated Radiation Therapy (IMRT) to the Pelvic for Post-Operative Patients with Endometrial Carcinoma (RTOG 0418).
Jhingran, A., Winter, K., Portelance, L., Miller, B., Salehpour, M., Gaur, R., Souhami, L., Small, W., Berk, L. and Gaffney, D. |
Oral Presentation: 35
Mon., 9/22, 10:25 AM
Session E, Room 257 |
| Head & Neck Cancer | |
| Multi-institutional Trial of IMRT for Early Oropharyngeal Cancer: Acceleration via Simultaneously Incorporated Boost (SIB) (RTOG 0022).
Eisbruch, A., Harris, J., Garden, A., Chao, C., Straube, W., Harari, P., Sanguineti, Jones, Bosch, W. and Ang, K. |
Oral Presentation: 219
Wed., 9/24, 1:50 PM
Session Y, Room 107 |
| Phase II Multi-Institutional Study of Intensity-Modulated Radiation Therapy (IMRT) ± Chemotherapy for Nasopharyngeal (NPC) Carcinoma: Preliminary Clinical Results of RTOG 0225.
Lee, N., Harris, J., Garden, A., Straube, W., Bosch, W., Morrison, W., Quivey, J., Thorstadt, W., Jones, C. and Ang, K. |
Oral Presentation: 217
Wed., 9/24, 1:30 PM
Session Y, Room 107 |
| Increased Oral Mucositis After IMRT vs Non-IMRT When Combined with Cetuximab and Cisplatin or Docetaxel for Head and Neck Cancer: Preliminary Results of RTOG 0234.
Khuntia, D., Harris, J., Bentzen, S., Kies, M., Myers, J., Foote, R., Machtay, M., Straube, W., Ang, K. and Harari, P. |
Oral Presentation: 70
Tues., 9/23, 11:30 AM
Session H, Room 253 |
| Lung Cancer | |
| Correlation of EGFR Expression by IHC & FISH to Predict Patient Outcome: A Phase II RTOG 0324 Study for Patients With Stage III NSCLC Treated by Chemoradiotherapy & Cetuximab (C225).
Komaki, R., Paulus, R., Olsen, C., Conway, P., Ang, K., Trotti, A., Blumenschein, G., Curran, W., Choy, H. and Hirsch, F. |
Poster Discussion: 1006
Mon., 9/22, 10:15 AM
Session 1, Room 156 |
| Pancreatic Cancer | |
| Validation of Randomization Based on Patient Genotype: Results from RTOG 9704 Trial in Pancreatic Cancer and Implications for Future Trial Design.
Farrell, J., Bae, K., Fromm, M., Regine, W., Abrams, R., Safran, H., Hoffman, J., Benson, A., MacDonald, J., Dicker, A. and Elsaleh, H. |
Oral Presentation: 31
Mon., 9/22, 11:05 AM
Session D, Room 252 |
| Total Nodes Examined (TNE) and Number of Positive Nodes (NPN) Predict Survival in Patients Undergoing Pancreaticoduodenectomy (PD) Followed by Adjuvant Chemoradiation (CRT) for Pancreatic Cancer-A Secondary Analysis of RTOG 9704.
Showalter, T., Winter, K., Berger, A., Regine, W., Abrams, R., Safran, H., Hoffman, J., Benson, A., MacDonald, J. and Willett, C. |
Oral Presentation: 29
Mon., 9/22, 10:35 AM
Session D, Room 252 |
| Prostate Cancer | |
| A Prospective Phase I/II Study Using Proton Beam Radiation to Deliver 82GyE to Men with Localized Prostate Cancer: Preliminary Results of ACR 0312.
Zietman, A., Rossi, C., Bae, K., Coen, J., Slater, J., Lunt, M. and Shipley, W. |
Oral Presentation: 169
Wed., 9/24, 11:35 AM
Session S, Room 253 |
| Phase II Trial of Combined High Dose Rate Brachytherapy and External Beam Radiotherapy for Adenocarcinoma of the Prostate: Preliminary Results of RTOG 0321.
Hsu, I.-C., Bae, K., Shinohara, K., Pouliot, J., Purdy, J., Ibbott, G., Speight, J., Vigneault, E., Ivker, R. and Sandler, H. |
Poster Discussion: 1045
Tues., 9/23, 11:00 AM
Session 4, Room 157 |
| A Model for Distant Metastasis Incorporating Tissue Biomarkers from Prostate Cancer Patients in Radiation Therapy Oncology Group (RTOG) 9202.
Pollack, A., Bae, K., Khor, L., Hammond, E., Chakravarti, A., Dicker, A., Brereton, H., Byhardt, R., Venketesan, V. and Sandler, H. |
Oral Presentation: 126
Tues., 9/23, 3:05 PM
Session N, Room 253 |
| Protein Kinase A RI-alpha Overexpression Is Associated With Prostate Cancer Outcome in Men Treated With Androgen Deprivation and Radiotherapy: A Secondary Analysis of RTOG 9202.
Khor, L.-Y., Bae, K., Al-Saleem, T., Hammond, M., Fisher, B., Byhardt, R., Asbell, S., Shipley, W., Sandler, H. and Pollack, A. |
Oral Presentation: 119
Tues., 9/23, 1:55 PM
Session N, Room 253 |
| Risk Factors for Grade > 2 Late Bladder Toxicity Among Patients Treated on Protocol RTOG 9406.
Tucker, S., Dong, L., Michalski, J., Bosch, W., Winter, K., Mohan, R., Kuban, D., Cheung, M., Lee, A., and Cox, J. |
Oral Presentation: 145
Tues., 9/23, 2:05 PM
Session Q, Room 258 |
| Rectal Cancer | |
| 5-Year Results of RTOG 0012 Randomized Phase II Study of Neoadjuvant Combined Modality Chemoradiation for Distal Rectal Cancer.
Mohiuddin, M., Paulus, R., Mitchell, E., Hanna, N., Yuen, A., Nichols, C., Shane, R., Hayostek, C. and Willett, C. |
Poster: 2164
Poster - Exhibition Hall |
| Elective Clinical Target Volumes for Conformal Therapy in Anorectal Cancer: An RTOG Consensus Panel Contouring Atlas.
Myerson, R., Garofalo, M., el Naqa, I., Abrams, R., Bosch, W., Das, P., Gunderson, L., Hong, T., Kim, J., Willett, C. and Kachnic, L. |
Oral Presentation: 156
Wed., 9/24, 10:45 AM
Session R, Room 252 |
|
|
CONTACT: Sharon Hartson Stine
Mobile: 609.458.5604
shartson@acr-arrs.org
RTOG Study: Weight, Not Diabetes, Related to Prostate Cancer Mortality
Chicago, June 2, 2008 - Diabetic men with prostate cancer are no more likely to die from their cancer than are men who are not diabetic. However, increased body weight does increase the likelihood of prostate cancer-related death according to new research from the Radiation Therapy Oncology Group (RTOG) presented at the American Society of Clinical Oncology's 44th Annual Meeting in Chicago. RTOG, an NCI-funded national clinical trials group, is a clinical research component of the American College of Radiology (ACR).
Recent research has shown that men with diabetes have a lower risk of developing prostate cancer. However little was known about the role of diabetes in those men who do develop prostate cancer. "Based on the results of our investigation, we now know that the real risk factor is not diabetes, but rather obesity," said lead author Matthew Smith, M.D., Ph.D., of the Department of Medicine at Harvard Medical School. "We controlled for age, race, tumor stage, Gleason score, PSA, diabetes, weight and treatment assignment and found that weight, not diabetes, was the better predictor of prostate cancer mortality."
Using data from a large randomized trial, RTOG 9202, of 1554 men treated with radiation therapy and short-term versus long-term adjuvant hormone therapy for locally advanced prostate cancer, RTOG investigators were able to look at the relationship between diabetes and cancer-related death, non-cancer-related death, and overall mortality. The researchers found that diabetes was significantly associated with deaths from all causes and deaths from non-prostate cancer-related causes, but not prostate cancer deaths. In contrast weight was associated with a higher incidence of prostate cancer deaths but not deaths from all causes or non-prostate cancer deaths.
"The RTOG is proud that our vast database enables researchers to compile and analyze data that can help extend and improve the lives of cancer patients. RTOG studies like this answer unique questions and further oncology research for the benefit of patients everywhere," said Walter J. Curran, Jr., the RTOG Group Chair, and the Lawrence W. Davis Professor and Chair of the Department of Radiation Oncology in the Emory School of Medicine and Chief Medical Officer of the Emory Winship Cancer Institute.
For more information or to arrange an interview with an RTOG spokesperson, please contact Sharon Hartson at 609.458.5604 or shartson@acr-arrs.org.
# # #
ASCO Abstract #5013, Diabetes and Mortality in Men with Locally Advanced Prostate Cancer: Analyses of RTOG 92-02 , is available at www.abstract.asco.org/AbstView_55_33550.html.
Information about RTOG is available at www.rtog.org.
In addition to Dr. Smith, authors include: B. Kyounghwa, Ph.D., Radiation Therapy Oncology Group, Philadelphia, PA; J. A. Efstathiou, M.D., and W. U. Shipley, M.D., Massachusetts General Hospital, Boston, MA; G. E. Hanks, M.D., Fox Chase Cancer Center, Philadelphia, PA; M. V. Pilepich, M.D., University of California Los Angeles, Los Angeles, CA; and H. M. Sandler, M.D., University of Michigan, Ann Arbor, MI. The research was funded by National Cancer Institute grants CA21661, CA37422, and 32115.
|
|
 |
|
|
|
